New method for delivering HIV treatment through skin and mouth
Ionic liquid-based nanoemulsion containing combination antiretroviral drugs for the oral and transdermal treatment of HIV infection
This study is looking at a new way to deliver HIV medications using tiny droplets in a special liquid, which could make the treatment work better and have fewer side effects, so patients might find it easier and safer to stick to their therapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10836933 on NIH RePORTER |
What this research studies
This research investigates a novel approach to delivering a combination of antiretroviral drugs for HIV treatment using ionic liquid-based nanoemulsions. The goal is to enhance the effectiveness and reduce side effects of existing oral medications by improving their bioavailability and allowing for non-invasive transdermal administration. Patients may benefit from a more convenient and potentially safer method of receiving their HIV therapy, which could lead to better adherence and outcomes. The study will explore how these new formulations can be developed and tested for their effectiveness in treating HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV who are currently on antiretroviral therapy or are in need of effective treatment options.
Not a fit: Patients who are not living with HIV or those who are already effectively managing their condition with existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective and less invasive way to manage their HIV treatment.
How similar studies have performed: While the use of ionic liquids in drug delivery is a novel approach, similar strategies have shown promise in enhancing drug bioavailability in other therapeutic areas.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Date, Abhijit a — University of Arizona
- Study coordinator: Date, Abhijit a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.